TITLE

INFLIXIMAB USAGE FOR CROHN'S DISEASE: A WEST MIDLANDS SURVEY

PUB. DATE
April 2004
SOURCE
Gut;Apr2004 Supplement 3, Vol. 53, pA101
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Infliximob, a chimeric monoclonal anti-TNF antibody, was licensed for usage in Crohn's disease in Great Briatin in 1999 and was believed to represent a major advance in therapeutic options. However, there remain few data on medium to long term follow up on patients treated with Infliximab. Only around half of West Midlands' gastroenterologists reported usage of Infliximab prior to NICE guidelines. Some patients had sustained benefit but a proportion still required surgery, others required multiple infusions. Further follow up and surveillance may clarify its clinical and health economic impact.
ACCESSION #
13219209

 

Related Articles

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sign out of this library

Other Topics